Nestibil (Bilastine)

Bilastine selectively blocks peripheral H1 receptors, preventing histamine from binding to these sites on mast cells, blood vessels and sensory nerves. This inhibition stops the cascade that leads to vasodilation, increased vascular permeability, and nerve stimulation, thereby alleviating allergic symptoms.

The appropriate dose of Nestibil is determined by the prescribing healthcare professional based on the patient’s condition, age, renal function and other clinical factors. Patients should follow the prescriber’s instructions and not alter the dose without medical advice.

Safety data for bilastine in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Nestibil.

To request Nestibil, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with first‑generation antihistamines, bilastine offers a non‑sedating profile and selective H1 antagonism, reducing the risk of drowsiness. Relative to other second‑generation agents, it has a similar efficacy for allergic rhinitis and urticaria, with a low potential for drug‑drug interactions.

Nestibil should be stored at ambient temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and discard any product that shows signs of damage or discoloration.

Nestibil is taken orally, usually with a glass of water. It can be taken with or without food, but patients should avoid taking it simultaneously with antacids or fruit juices that may affect absorption.

Serious but rare adverse events include anaphylaxis, Stevens‑Johnson syndrome, angioedema, severe hepatic injury and cardiac arrhythmias. Patients should seek immediate medical attention if they experience symptoms such as swelling of the face or throat, rash, fever, or unexplained heart palpitations.

Nestibil is contraindicated in individuals with known hypersensitivity to bilastine or any excipients in the formulation. Caution is advised for patients with severe renal impairment, and it should be avoided in combination with strong CYP3A4 inhibitors unless supervised by a physician.